Table 2.
First biotherapy and outcomes in CCPD and gout in western France
| CCPD | Gout | p value | |
|---|---|---|---|
| Number | 15 (32.6) | 31 (67.4) | |
| First biotherapy | 0.708 | ||
| Anakinra | 14 (93.3) | 31 (100.0) | |
| Etanercept | 1 (6.4) | 0 | |
| Place of introduction | 0.497 | ||
| Consultation | 4 (26.7) | 13 (41.9) | |
| Hospitalization | 11 (73.3) | 18 (58.1) | |
| Reason for introduction | 0.273 | ||
| Crisis | 2 (13.3) | 9 (29.0) | |
| Crisis/long-term | 3 (20.0) | 9 (29.0) | |
| Long-term | 10 (66.7) | 13 (41.9) | |
| Stopping reason | 0.048 | ||
| Death | 0 (0.0) | 2 (6.5) | |
| In progress | 3 (20.0) | 5 (16.1) | |
| Side effect | 6 (40.0) | 4 (12.9) | |
| Ineffective | 4 (26.7) | 2 (6.5) | |
| Scheduled | 2 (13.3) | 18 (58.1) | |
| Efficiency (n = 45) | 5/14 (35.7) | 28/31 (90.3) | < 0.001 |
| Side effect (n = 44) | 6/14 (42.9) | 8/30 (26.7) | 0.490 |
| Stop for side effect (n = 44) | 6/14 (42.9) | 4/30 (13.3) | 0.084 |
Data are presented as n (%)
CCPD calcium pyrophosphate crystal deposition